Dag Aarsland, MD, PhD’s research involves a wide variety of topics within psychiatry and neuropsychiatry of older adults, with a focus on neuropsychiatric problems in people with Parkinson’s disease and dementia with Lewy bodies. A key current research aim is to develop biomarker research. He has been actively involved in the international task forces developing diagnostic criteria for dementia and mild cognitive impairment in Parkinson’s disease and dementia with Lewy bodies. Together with key colleagues he developed a ‘Parkinson-spectrum Memory Clinic’ focusing on Parkinson’s and dementia with Lewy bodies patients at South London and Maudsley NHS Foundation Trust. He played a central role in the study and subsequent paper that led to the licensing of rivastigmine for Parkinsonian dementia. Professor Aarsland has published more than 400 scientific papers and numerous books and book chapters and has served as an invited speaker many psychiatric and neurological international scientific conferences.